{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:28:03Z","timestamp":1791041283389,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1007\/s00432-003-0441-y","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T02:09:32Z","timestamp":1576116572000},"page":"316-319","source":"Crossref","is-referenced-by-count":29,"title":["Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer"],"prefix":"10.1007","volume":"129","author":[{"given":"A.","family":"Klippstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. G.","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"H\u00f6ffken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,5,17]]},"reference":[{"key":"0441_CR1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K, et al (1996) Bendamustine hydrochloride activity against doxorubicine-resistant human breast carcinoma cell lines. Anti Cancer Drugs 7:415\u2013421","journal-title":"Anti Cancer Drugs"},{"key":"0441_CR2","first-page":"571","volume":"52","author":"Reck","year":"1998","unstructured":"Reck M, Haering B, Koschel G, et al (1998) Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen Bronchialkarzinoms mit Bendamustin\u2014Eine Phase-II-Studie. Pneumologie 52:571\u2013574","journal-title":"Pneumologie"},{"key":"0441_CR3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/PL00002397","volume":"177","author":"Rahn","year":"2001","unstructured":"Rahn AN, Schilcher RB, Adamietz IA, et al (2001) Palliative Radiochemotherapie mit Bendamustin bei fortgeschrittenen Tumorrezidiven im HNO-Bereich. Strahlenther Onkol 177:189\u2013194","journal-title":"Strahlenther Onkol"},{"key":"0441_CR4","first-page":"1","volume":"17","author":"Bremer","year":"1996","unstructured":"Bremer K, Roth W (1996) Bendamustine, a low-toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumordiagn Ther 17:1\u20136","journal-title":"Tumordiagn Ther"},{"key":"0441_CR5","first-page":"458","volume":"14","author":"Matthias","year":"1995","unstructured":"Matthias M, Preiss R, Sohr R, Possinger K (1995) Pharmakokinetics of bendamustine in patients with malignant tumors. Proc Am Assoc Clin Oncol 14:458 [abstr]","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"0441_CR6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s004320050225","volume":"124","author":"H\u00f6ffken","year":"1998","unstructured":"H\u00f6ffken K, Merkle Kh, Sch\u00f6nfelder M, et al (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer:a phase II study. J Cancer Res Clin Oncol 124:627\u2013632","journal-title":"J Cancer Res Clin Oncol"},{"key":"0441_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/PL00008463","volume":"126","author":"Sch\u00f6ffski","year":"2000","unstructured":"Sch\u00f6ffski P, Hagedorn T, Gr\u00fcnwald V, et al (2000) Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours. J Cancer Res Clin Oncol 126:41\u201347","journal-title":"J Cancer Res Clin Oncol"},{"key":"0441_CR8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","volume":"11","author":"Sch\u00f6ffski","year":"2000","unstructured":"Sch\u00f6ffski P, Seeland G, Engel H, et al (2000) Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 11:729\u2013734","journal-title":"Ann Oncol"},{"key":"0441_CR9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","volume":"127","author":"Kath","year":"2001","unstructured":"Kath R, Blumenstengel K, Fricke HJ, H\u00f6ffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48\u201354","journal-title":"J Cancer Res Clin Oncol"},{"key":"0441_CR10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.1993.tb00165.x","volume":"50","author":"Wijermans","year":"1993","unstructured":"Wijermans PW, Gerrits WB, Haak HL (1993) Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292\u2013296","journal-title":"Eur J Haematol"},{"key":"0441_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/10428199909169620","volume":"35","author":"Bastie","year":"1999","unstructured":"Bastie JN, Cazals-Hatem D, Daniel MT, et al (1999) Five years follow-up after 2-chlorodeoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+lymphocytopenia after treatment. Leuk Lymphoma 35:555\u2013565","journal-title":"Leuk Lymphoma"},{"key":"0441_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1055\/s-2001-11316","volume":"126","author":"Kath","year":"2001","unstructured":"Kath R, Blumenstengel K, Fricke HJ, et al (2001) Bendamustin, Vincristin, Prednisolon (BOP) in der Therapie von fortgeschrittenen niedrig malignen Non-Hodgkin-Lymphomen. Dtsch med Wschr 126:198\u2013202","journal-title":"Dtsch med Wschr"},{"key":"0441_CR13","unstructured":"Ruffert K, Jahn H, Jorke D (1988) A comparative study of cytostasan, methotrexate (MTX) plus fluorouracil (5-FU) and CMF in advanced breast cancer (abstract). Proc Eur Soc Med Oncol 240"},{"key":"0441_CR14","first-page":"341","volume":"59","author":"Brockmann","year":"1989","unstructured":"Brockmann B, Kirchhof I, Geschke E, Schmidt UM (1989) Therapieergebnisse und toxische Nebenwirkungen der Kombination Cytostasan, Adriamycin und Vincristin als \"second line\"-Therapie beim metastasierenden Mammakarzinom. Arch Geschwulstforsch 59:341\u2013346","journal-title":"Arch Geschwulstforsch"},{"key":"0441_CR15","unstructured":"Sayer HG, Vogt T, Hoffmann K, Wollina K, M\u00fcgge LO, H\u00f6ffken K (2000) High response-rate of short duration with a double high-dose-chemotherapy regimen of doxorubicin\/paclitaxel\/cyclophosphamide\/thiotepa [ATCT] and peripheral blood progenitor cell support in patients with metastatic breast cancer. Bone Marrow Transplantation 26[Suppl 1]:S 34"},{"key":"0441_CR16","first-page":"18a","volume":"18","author":"Schadeck-Gressel","year":"1998","unstructured":"Schadeck-Gressel C, Eberhardt B, Westerhausen M (1998) Bendamustine as immune suppressive agent in five cases of therapy refractory autoimmune thrombocytopenic purpura (ITP). Proc Am Soc Clin Oncol 18:18a [abstr 65]","journal-title":"Proc Am Soc Clin Oncol"},{"key":"0441_CR17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/ajrccm\/143.2.437","volume":"143","author":"Siminski","year":"1991","unstructured":"Siminski J, Kidd P, Phillips GD (1991) Reversed helper\/suppressor T-lymphocyte ratio in bronchoalveolar lavage from patients with breast cancer and Pneumocystis carinii Pneumonia. Am Rev Respir Dis 143:437\u2013440","journal-title":"Am Rev Respir Dis"},{"key":"0441_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0954-6111(93)90146-Q","volume":"87","author":"Kane","year":"1993","unstructured":"Kane GC, Troshinsky MB, Peters SP, Israel HL (1993) Pneumocystis carinii pneumonia associated with weekly methotrexate: cumulative dose of methotrexate and low CD4 cell count may predict this complication. Respir Med 87:153\u2013155","journal-title":"Respir Med"},{"key":"0441_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199001183220304","volume":"322","author":"Phair","year":"1990","unstructured":"Phair J, Munoz A, Detels R, et al (1990) The risk of Pneumocystis carinii pneumonia among men infected with human immundeficiency virus type 1. Multicenter AIDS cohort study group. N Engl J Med 322:161\u2013165","journal-title":"N Engl J Med"},{"key":"0441_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s150100070041","volume":"28","author":"Gl\u00fcck","year":"2000","unstructured":"Gl\u00fcck T, Geerdes-Fenge HF, Straub RH, et al (2000) Pneumocystis carinii Pneumonia as acomplication of immunsuppressive therapy. Infection 28:227\u2013230","journal-title":"Infection"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-003-0441-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-003-0441-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-003-0441-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T02:09:36Z","timestamp":1576116576000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-003-0441-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["0441"],"URL":"https:\/\/doi.org\/10.1007\/s00432-003-0441-y","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}